Aequs Ltd. Share Price

Aequs: $1 billion order book, four straight years of losses

Aequs Limited (NSE: AEQUS) grew Q1 FY27 consolidated revenue 55% to ₹395.5 crore. Aerospace, at 81% of revenue, grew 40% to ₹322.2 crore. The stock is up 96% since its December 2025 listing and trades at 12.4 times book value. What happened Aerospace EBITDA rose 35% to ₹73.1 crore, though it was below the ₹101 crore in Q4 FY26. Utilisation was 70% globally and 78% in India. The aerospace order book crossed $1 billion, rising 13% QoQ from $889 million. Aequs signed two new aerostructures Tier-1 agreements and won its first contract to manufacture Airbus A320 wheels for Safran Landing Systems under a 15-year sole-source deal. Why it matters The order book change matters. The portfolio now has 5,740 qualified products, with 86 added in Q1 alone. The top three customer groups have an average relationship of 15 years. My view Four consecutive years of losses: ₹(110), ₹(14), ₹(102) and ₹(113) crore. Operating profit is positive. Interest, depreciation and other costs consume it. IPO proceeds cut net debt to equity to 0.34 times from 0.88 times. But operating cash flow turned negative at ₹41.4 crore as working capital expanded. Full year FY27 capex is ₹660 crore, including ₹160 crore for aerospace. The Hosur ecosystem needs ₹1,900 crore over 10 years, with revenue from FY29. JM Financial downgraded to Reduce in May 2026 with a ₹210 target. The stock closed at ₹275, about 31% above that. What I am watching Q2 FY27 results, operating cash flow turning positive, and the first consolidated profit. On the chart, ₹200 is the IPO listing area and the key support. My stance: Wait for one profitable quarter. The order book is real. The profits are not yet there. Disclosure: I do not hold a position in Aequs Limited at the time of writing. This is not investment advice.

See More

Aequs Jumps around 6% on Capex News, Tests Range High

closed at 260.10, up 5.71%, after the precision engineering and contract manufacturing company outlined a Rs 660 crore capex budget for FY27, aimed at expanding its aerospace and consumer businesses. As per a Moneycontrol report, the company's board has separately approved a Rs 650 crore equity infusion through warrants issued to the promoter group, with 50% payable upfront on allotment, and another fundraise is anticipated in FY28 to sustain the growth push. On the chart, this move has taken price right up to the descending trendline resistance near 270-274 that has capped rallies since July, after the stock found support multiple times near the 215 zone over the past few months. RSI at 68.04, above the signal line at 45.05, reflects the strength of today's move, with volume also picking up sharply on the breakout attempt. Resistance: 270-274 (descending trendline), then 280 (prior swing high). Support: 246-252 (near-term), then 215 (range low). Whether today's capex-driven move is enough to close above the trendline on a sustained basis, or whether the stock fades back into the recent range, is what needs to be watched over the coming sessions. A strong fundamental trigger testing a well-defined trendline resistance is a useful setup to track — the follow-through, not the news itself, confirms the technical outcome. Disclaimer:This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

See More

Aequs Ltd Engineering Company Fundamental Analysis

Aequs is an engineering-led, vertically integrated contract manufacturing company with a strong presence in aerospace and an emerging consumer manufacturing business. Its aerospace ecosystem covers precision components, machining, forging, surface treatment and assemblies, allowing the company to serve global OEMs and Tier-1 suppliers through an integrated manufacturing model. The consumer segment is being scaled across consumer electronics and other products, creating an additional long-term growth avenue. FY26 revenue increased 33% YoY to ₹1,230.4 crore and EBITDA rose 43% to ₹154.5 crore, with EBITDA margin improving to 13%. However, the company remained loss-making, reporting a consolidated PAT loss of ₹113.3 crore for FY26. Q1 FY27 revenue increased a strong 54.8% YoY to ₹395.5 crore, but net loss remained high at ₹53.2 crore. Aerospace revenue grew 39.9% to ₹322.2 crore and generated a segment profit of ₹73.1 crore, while consumer revenue surged 190.4% to ₹73.4 crore but recorded a ₹36.1 crore segment loss. The major growth drivers are increasing aerospace outsourcing, new programs with global customers, capacity utilisation and the ramp-up of consumer manufacturing. The IPO has also substantially strengthened the balance sheet; FY26 debt-equity declined to around 0.23x and net worth increased sharply. However, the current valuation requires close attention: Groww reports a market capitalisation of about ₹16,287 crore, negative TTM earnings, P/B around 10.96x and ROE of -7.41%. The key risks are continued consolidated losses, high depreciation and finance costs, execution risk in new consumer facilities, working-capital requirements and the substantial valuation relative to present earnings. The central factor to monitor is whether strong aerospace growth and consumer scale-up can eventually translate into sustainable consolidated profitability.

See More

News update in Aequs has just approved equity infusion

Aequs has just approved a ₹650 crore equity infusion via promoter warrants to expand its aerospace and consumer businesses, including its Hosur facility. This move will increase promoter holding to 60.73% and strengthen the company’s ability to raise borrowings for future growth. 🔑 Key Highlights Equity Infusion: ₹650 crore through preferential warrants issued to Mellwood Trustee Services, part of the Melligeri Private Family Foundation. Payment Terms: ₹325 crore upfront (twice the regulatory minimum), balance payable upon warrant exercise within 18 months. Promoter Holding: Will rise from 59.09% to 60.73% after full conversion. Expansion Focus: Aerospace and consumer manufacturing, especially the Hosur facility, subsidiaries, and joint ventures. Timeline: Conversion into shares and full payment expected by December 31, 2027. 📊 Financial & Market Context Aspect Details Order Book Aerospace order book crossed USD 1 billion in Q1 FY27, up 13% sequentially. Revenue Growth Q1 FY27 consolidated revenue: ₹3,955 million, up 55% YoY. Consumer Segment Revenue surged 190% YoY to ₹734 million, now contributing 19% of total revenue. Equity Price Warrants priced at ₹231.55 per share, based on VWAP calculations. 📌 Strategic Implications Aerospace Growth Engine: Strong demand and customer confidence are driving program wins faster than expected. Consumer Manufacturing Scale-Up: Rapid expansion in electronics and consumer goods manufacturing is diversifying revenue streams. Capital Structure: The infusion provides a base for raising term borrowings, ensuring liquidity for aggressive expansion. Shareholder Approval: An Extraordinary General Meeting (EGM) is scheduled for October 22, 2026, to seek shareholder nod. ⚠️ Risks & Considerations Regulatory Approvals: Expansion plans hinge on SEBI and shareholder clearances. Execution Risk: Scaling aerospace and consumer facilities requires timely commissioning and cost control.

See More

Aequs Approves ₹650 Crore Preferential Warrant Issue

has approved a preferential issue of up to 28,071,690 warrants to Mellwood Trustee Services Private Limited, trustee of Melligeri Private Family Foundation and part of the promoter group. Each warrant will be convertible into one equity share at ₹231.55, aggregating to approximately ₹650 crore. The issue is subject to shareholder and other applicable approvals. A minimum of ₹325 crore will be payable at subscription and allotment, with the balance due upon exercise of the warrants. The warrants can be converted in one or more tranches on or before December 31, 2027. If not exercised within the specified period, the entitlement will lapse and the ₹325 crore paid at subscription will be forfeited. The investor currently holds 14.99% in Aequs. Assuming full conversion, its holding would rise to 18.40%, while promoter and promoter group shareholding would increase from 59.09% to 60.73%. The warrants will not carry voting rights until conversion into equity shares. The company has stated that the preferential issue will not result in any change in control or management. An EGM is scheduled for October 22, 2026, to seek shareholder approval. The issue price of ₹231.55 is the applicable floor price determined under SEBI ICDR Regulations. Disclosure: I do not hold any position or financial interest in the mentioned stock.

See More

Aequs Limited Board Approves Equity Infusion

Rs 650 Cr Infusion through Warrants by Promoter Group; 50 per cent Payable Upfront Of the total issue size of approximately ₹650 crore, ₹325 crore will be payable upfront upon allotment of the warrants, representing 50 per cent of the issue size, and twice the regulatory minimum. The balance will be payable upon exercise of the warrants. In accordance with applicable regulations, warrant may be exercised within 18 months from the date of allotment. However, conversion of warrants into equity shares, by making payment of balance consideration, shall take place on or before December 31, 2027. Promoter has undertaken to pay the balance consideration in full, irrespective of the market price of the Company’s shares at the time of exercise. The Company has received an investment commitment letter dated September 25, 2026, from Promoter to this effect. The issue price of Rs 231.55 is the floor price determined under Regulation 164 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 — the higher of the 90-trading-day and the 10-trading-day volume weighted average price of the Company’s shares preceding the relevant date of September 22, 2026. On full conversion of the warrants, the aggregate Oholding of the Promoter and Promoter Group in the Company will increase from 59.09 per cent to 60.73 per cent. Opinion : This News will have postive impact on the stock price in short to long term Disclaimer : This is not a buy sell or hold recommendation. I do not hold this stock

See More